Huntington disease

Neurocrine

Pharma

Neurocrine's Ingrezza nabs Huntington's nod to rival Austedo

Neurocrine Biosciences’ Ingrezza is debuting in a treatment area with hundreds of millions of dollars of revenue potential.

Fraiser Kansteiner Aug 22, 2023 9:53am

Teva

Teva's flagship drug Austedo scores new approval at the FDA

Feb 21, 2023 4:28pm

Huntingtons disease

Teva launches digital Huntington's disease campaign

Sep 28, 2022 9:05am